Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $11.8 million.

  • Fortress Biotech's Net Cash Flow rose 16820.38% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.5 million, marking a year-over-year increase of 29178.54%. This contributed to the annual value of -$24.5 million for FY2024, which is 7484.35% up from last year.
  • As of Q3 2025, Fortress Biotech's Net Cash Flow stood at $11.8 million, which was up 16820.38% from -$17.0 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Net Cash Flow registered a high of $56.5 million during Q1 2021, and its lowest value of -$65.7 million during Q2 2023.
  • Its 5-year average for Net Cash Flow is -$7.8 million, with a median of -$14.9 million in 2021.
  • The largest annual percentage gain for Fortress Biotech's Net Cash Flow in the last 5 years was 627989.07% (2021), contrasted with its biggest fall of 21035.08% (2021).
  • Fortress Biotech's Net Cash Flow (Quarter) stood at $53.6 million in 2021, then tumbled by 155.26% to -$29.6 million in 2022, then surged by 129.1% to $8.6 million in 2023, then crashed by 124.37% to -$2.1 million in 2024, then skyrocketed by 663.16% to $11.8 million in 2025.
  • Its Net Cash Flow was $11.8 million in Q3 2025, compared to -$17.0 million in Q2 2025 and $33.7 million in Q1 2025.